

# Say yes to less pain and more activity!

DUROLANE can be part of your treatment pathway. To learn more:



Visit: [DUROLANE.com](https://DUROLANE.com)  
Email: [customer-care-international@BioventusGlobal.com](mailto:customer-care-international@BioventusGlobal.com)  
Call: +31 (0)235548805

**DUROLANE**<sup>®</sup>  
hyaluronic acid, stabilized single injection

# Be one of many patients who have experienced the DUROLANE difference!

## What is OA?<sup>1</sup>

OA is a degenerative joint disease that can affect joint cartilage, bone, ligaments, and other tissues. OA typically develops over time, but it can develop much more rapidly after injury to a joint. The knees, hips, and shoulders are among the joints most commonly affected by OA.

OA symptoms often include **joint pain, stiffness, swelling, limited range of motion, clicking or popping sounds, and instability.**

## How is OA treated?<sup>2</sup>

No single OA treatment therapy works for everybody, and treatments vary in terms of risks, side effects, and duration of benefits.

It's important to discuss all available options with your doctor. Many doctors will recommend a stepped-care plan for each stage of the disease, an approach that includes a combination of different treatments.<sup>2</sup>

### Treatment options for mild OA may include:<sup>2,3</sup>

- Exercise
- Physical therapy
- Weight loss
- Oral or topical analgesics
- NSAIDs
- Hyaluronic acid (HA) injections
- Corticosteroid injections

### Treatment options for moderate OA may include:<sup>3</sup>

- HA injections
- Corticosteroid injections

**References:** 1. Arthritis Foundation. Osteoarthritis. Accessed May 4, 2022. [www.arthritis.org/diseases/osteoarthritis](http://www.arthritis.org/diseases/osteoarthritis). 2. Cleveland Clinic. Osteoarthritis. Last updated November 26, 2019. Accessed September 3, 2021. <https://my.clevelandclinic.org/health/diseases/5599-osteoarthritis>. 3. Arthroscopy Association of Canada, Kopka M, Sheehan B, et al. Arthroscopy Association of Canada position statement on intra-articular injections for knee osteoarthritis. *Orthop J Sports Med.* 2019;7(7):2325967119860110. doi:10.1177/2325967119860110 4. Maheu E, Bannuru RR, Herrero-Beaumont G, Ailali F, Bard H, Migliore A. Why we should definitely include intra-articular hyaluronic acid as a therapeutic option in the management of knee osteoarthritis: results of an extensive critical literature review. *Semin Arthritis Rheum.* 2019;48(4):563-72. doi:10.1016/j.semarthrit.2018.06.002 5. McIntyre L, Beach W, Bhattacharyya S, Yadalam S, Bisson B, Kim M. Impact of hyaluronic acid injections on utilization of pain management medications. *Am J Pharm Benefits.* 2017; 9(6):195-99. 6. Ågerup B, Berg P, Åkermark C. Non-animal stabilized hyaluronic acid: a new formulation for the treatment of osteoarthritis. *Biodrugs* 2005;19(1):23-30. doi:10.2165/00063030-200519010-00003 7. DUROLANE [package insert]. Durham, NC: Bioventus LLC; 2019. 8. Krockner D, Matziolis G, Tuischer J, et al. Reduction of arthrosis associated knee pain through a single intra-articular injection of synthetic hyaluronic acid. *Z Rheumatol.* 2006;65(4):327-31. doi:10.1007/s00393-006-0063-2 9. Lindqvist U, Tolmachev V, Kairemo K, Åström G, Jonsson E, Lundqvist H. Elimination of stabilised hyaluronan from the knee joint in healthy men. *Clin Pharmacokinet.* 2002;41(8):603-13. doi:10.2165/00003088-200241080-00004 10. Edsman K, Melin H, Näsström J. A study of the ability of DuroLANE™ to withstand degradation by free radicals while maintaining its viscoelastic properties. Poster presented at: 55th Annual Meeting of the Orthopaedic Research Society; February 22-25, 2009; Las Vegas, NV. Poster 1149. 11. Bioventus LLC. Supporting quantity of global patients treated with a single DUROLANE injection. Data on file, RPT-001056. 12. Leighton R, Åkermark C, Therrien R, et al. NASHA hyaluronic acid vs. methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. *Osteoarthritis Cartilage.* 2014;22(1):17-25. doi:10.1016/j.joca.2013.10.009 13. Zhang H, Zhang K, Zhang X, et al. Comparison of two hyaluronic acid formulations for safety and efficacy (CHASE) study in knee osteoarthritis: a multicenter, randomized, double-blind, 26-week non-inferiority trial comparing DuroLANE to Artz. *Arthritis Res Ther.* 2015;17(1):51. doi:10.1186/s13075-015-0557-x 14. Romero Jurado M, Enrique Fidalgo A, Rodríguez Villar V, Mar Medina J, Soler López B. Factors related with the time to surgery in waiting-list patients for knee prostheses. *Reumatol Clin.* 2013;9(3):148-55.

### Summary of Indications for Use:

**DUROLANE (3 mL):** Argentina, Australia,\* Brazil, Chile, Colombia, EU,\* India, Jordan, New Zealand,\* Russia, Switzerland,\* Turkey,\* United Arab Emirates: Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in Australia, EU and New Zealand for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes.

**Mexico:** Symptomatic treatment of mild to moderate knee osteoarthritis.

**Taiwan:** Treatment of pain in OA of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen.

**Canada:** Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been licenced for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, fingers and toes.

\*DUROLANE is also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure.

Full prescribing information can be found in product labeling, or at [DUROLANE.com](https://DUROLANE.com)

Bioventus, the Bioventus logo, and DUROLANE are registered trademarks of Bioventus LLC.

© 2022 Bioventus LLC. SMK-004503b 12/22



Innovations For Active Healing



# Less time seeking pain relief. More time doing what you love.

## Understanding OA and your treatment options

Weight control and reduction | Joint mobility training and strength exercises | Systemic pain relief (NSAIDs, other painkillers) | Local pain relief (HA and corticosteroid injections)

Balance  
Your OA  
Treatments

### Joint pain is local; why treat it systemically?

Per the OA treatment guidelines by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the American Academy of Orthopaedic Surgeons (AAOS), joint pain caused by OA is primarily treated with nonsteroidal anti-inflammatory drugs (NSAIDs), other oral painkillers, and opioids. The increased use of oral painkillers, such as NSAIDs and opioids, has been shown to lead to upper gastrointestinal issues, renal and cardiovascular adverse events, and risk of addiction and subsequent severe withdrawal.<sup>4</sup>

A single injection of DUROLANE has demonstrated the ability to reduce consumption of NSAIDs or other painkillers, while providing the same or greater pain relief.<sup>5</sup> In addition, DUROLANE helps to improve the function of the joint.<sup>6</sup>

*If you are not getting adequate pain relief from oral medications, physical therapy, or corticosteroid injections, it may be time to try DUROLANE.*

### What is DUROLANE?

DUROLANE is a unique, single-injection, high molecular weight hyaluronic acid (HA) therapy that provides long-lasting pain relief from knee OA and acts as a supplemental lubricant and shock-absorber. The HA in DUROLANE is made with the same material as the natural HA within the human body.<sup>7,8</sup>

### What makes DUROLANE unique?

Compared to other HAs, DUROLANE is made with unique, patented NASHA<sup>®</sup> technology, giving it a gel-bead structure. This makes it more resistant to degradation over time and provides long-lasting pain relief with a single injection.<sup>9,10</sup>



DUROLANE has helped more than 2 million patients enjoy more active lives.<sup>11</sup>

### How can DUROLANE help?

#### PAIN RELIEF

- DUROLANE offers patients powerful and lasting pain relief. DUROLANE also provides longer lasting pain relief compared to corticosteroids<sup>8,12</sup>
- In a clinical study, 95% of participants did not require additional medication from 10-18 weeks after treatment<sup>13</sup>

#### SAFETY

- Safe for repeated courses of therapy<sup>14</sup>
- A biofermented and non-avian source and minimally cross-linked, resulting in fewer adverse events and allergic reactions<sup>7,13</sup>

#### CONVENIENCE

- Clinically designed as a single injection, allowing for fewer clinic visits<sup>13</sup>
- Well tolerated, allowing patients to get back to daily activities soon after treatment<sup>7,8</sup>

#### IMPROVED QUALITY OF LIFE

- Provides long-lasting, powerful results, so patients can resume their daily activities<sup>9</sup>
- May help delay the need for joint replacement surgery<sup>14</sup>